| Pharmaceutical Information |
| Drug Name |
Carteolol hydrochloride |
| Drug ID |
BADD_D00373 |
| Description |
A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. |
| Indications and Usage |
For the treatment of intraocular hypertension and chronic open-angle glaucoma |
| Marketing Status |
approved |
| ATC Code |
C07AA15; S01ED05 |
| DrugBank ID |
DB00521
|
| KEGG ID |
D00599
|
| MeSH ID |
D002354
|
| PubChem ID |
40127
|
| TTD Drug ID |
D03GCJ
|
| NDC Product Code |
43898-0104; 61314-238 |
| UNII |
4797W6I0T4
|
| Synonyms |
Carteolol | OPC-1085 | OPC 1085 | OPC1085 | Carteolol Hydrochloride | Hydrochloride, Carteolol | Carteolol Monohydrochloride | Monohydrochloride, Carteolol |
|
| Chemical Information |
| Molecular Formula |
C16H25ClN2O3 |
| CAS Registry Number |
51781-21-6 |
| SMILES |
CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O.Cl |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
